natgillin/translations-raw huggingface dataset:
Safety and reversion to virulence trials have shown that the strain is safe for turkeys.
Preskusi varnosti in povrnitve virulence so pokazali, da je ta sev varen za purane.
However, precautionary measures have to be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys.
Toda, potrebno je slediti vsem varnostnim ukrepom, da bi se izognili neposrednemu ali posrednemu stiku med cepljenimi piščanci in purani.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above.
Ni podatkov o varnosti ter učinkovitosti ob uporabi tega cepiva s katerimkoli drugim zdravilom za uporabo v veterinarski medicini razen s prej omenjenimi.
Do not mix with any other veterinary medicinal product except those mentioned in section 4.8 and the diluent supplied for use with the product.
Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini razen s tistimi, navedenimi v poglavju 4.8. in vehiklom, ki je priložen za uporabo s tem cepivom.
Name and address of the manufacturers of the biological active substance(s)
Ime in naslov izdelovalcev biološke zdravilne učinkovine (zdravilnih učinkovin).
1 bottle of 200 ml
1 steklenica s po 200 ml
1000 doses 2000 doses
1000 odmerkov 2000 odmerkov
Do not use after the expiry date stated on the ampoule.
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ampuli.
Do not re-use opened containers of diluted vaccine.
Odprtih vsebnikov z razredčenim cepivom ne uporabite ponovno.
Ampoule carriers are stored in canister, and in liquid nitrogen containers.
Nosilci ampul so shranjeni v pločevinast škatli in v vsebnikih s tekočim dušikom.
• Thaw the contents of the ampoules rapidly by agitation in water at 25°C-30°C.
• Vsebino ampule odtajajte hitro s pretresanjem v vodi pri 25 °C do 30 °C.
For in ovo administration, an automated egg injection machine can be used.
Za in ovo injiciranje se lahko uporablja avtomatične naprave za injiciranje v jajca.
The vaccine induces an active immunity and a serological response against Infectious Bursal Disease and Marek's Disease in chickens.
Cepivo spodbudi aktivno imunost in serološki odgovor proti bolezni Gumboro in Marekovi bolezni pri piščancih.
As a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys.
Ker je cepivo živo, lahko cepljene ptice izločajo cepni sev virusa, ki se lahko prenese na purane.
Store the reconstituted vaccine at a temperature below 25°C.
Rekonstituirano cepivo hranite pri temperaturi do 25 °C.
Vaccinate only healthy birds.
Cepite samo zdrave živali.
For subcutaneous route:
Za subkutano dajanje:
Shelf life of the non-reconstituted vaccine: 36 months at -196°C Shelf life of the reconstituted vaccine: up to 2 hours at a temperature below 25°C.
Rok uporabnosti nerekonstituiranega cepiva: 36 mesecev pri -196 oC Rok uporabnosti po rekonstituciji: do dve uri pri temperaturi do 25 °C.
Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Merial attenuated vaccines against Newcastle disease and Infectious bronchitis.
Podatki o varnosti in učinkovitosti so pokazali, da je to cepivo varno aplicirati na isti dan vendar ne zmešano z Merialovimi atenuiranimi cepivi proti atipični kokošji kugi in infekcioznemu bronhitisu.
Use sterile and antiseptic-free and/or disinfectant-free equipment for injections purposes.
Za injiciranje uporabljajte le sterilne instrumente, brez aseptikov in/ali dezinficiensov.
The onset of protection is from 4 days.
Zaščita nastopi od 4. dneva dalje.
Open ampoules holding them at arm's length in order to prevent any risk of injury should an ampoule break.
Ampule odpirajte tako, da jih držite na oddaljenosti dolžine roke, da bi lahko preprečili možnost poškodbe, če bi se ampula zlomila.
Suspension and solvent for suspension for injection
Suspenzija in vehikel za suspenzijo za injiciranje
• To reduce mortality, clinical signs and lesions of Marek's disease.
• Za zmanjšanje smrtnosti, ublažitev kliničnih znakov in poškodb zaradi Marekove bolezni.
In ovo route: one single injection of 0.05 ml per egg at 18 days of embryonation.
Pri in ovo vnosu - enkratno injiciranje 0,05 ml pripravljenega cepiva na jajce 18. dan embrionalnega razvoja.
• Repeat the thawing, opening, transfer and rinsing operations for the appropriate number of ampoules to be reconstituted in the diluent; either 1 ampoule of 1,000 doses of vaccine per 200 ml of diluent (or 1 ampoule of 2,000 doses of vaccine per 400 ml of diluent) for subcutaneous administration, or 4 ampoules of 1,000 doses of vaccine per 200 ml of diluent (or 4 ampoules of 2,000 doses of vaccines per 400 ml of diluent) for in ovo administration.
• Odtajanje, odpiranje in izpiranje vsebine ampule z vehiklom ponovite glede na potrebno število ampul, ali 1 ampulo s 1,000 odmerki cepiva za 200 ml vehikla (ali 1 ampulo z 2,000 odmerki cepiva za 400 ml vehikla) za vnos v podkožje ali 4 ampule s 1,000 odmerki cepiva za 200 ml vehikla (ali 4 ampule z 2,000 odmerki cepiva za 400 ml vehikla) za vnos in ovo.
• To prevent mortality and to reduce clinical signs and lesions of Infectious Bursal disease.
• Za preprečevanje smrtnosti, ublažitev kliničnih znakov in poškodb, ki so posledica bolezni Gumboro.
Lay: Do not use in breeding birds and birds in lay.
Nesnost: Ne uporabite pri vzrejnih pticah in pticah v obdobju valjenja.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALCI BIOLOŠKE ZDRAVILNE UČINKOVINE (ZDRAVILNIH UČINKOVIN) IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJE
- (polypropylene) bottle of 200ml of diluent.
- (polipropilenska) steklenica z 200 ml vehikla.
Read the package leaflet supplied with the vaccine vial.
Preberite Navodilo za uporabo, ki je priloženo viali s cepivom.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Merial attenuated vaccines against Marek's disease Rispens strain.
Podatki o varnosti in učinkovitosti so pokazali, da je to cepivo varno mešati z Merialovim atenuiranim cepivom proti Marekovi bolezni, sev Rispens.
- (polyvinylchloride) bag of 200ml, 400ml, 600ml, 800ml, 1000ml, 1200ml, 1400ml, 1600ml,
- (polivinilkloridna) vrečka z 200 ml, 400 ml, 600 ml, 800 ml, 1000 ml, 1200 ml, 1400 ml, 1600 ml,
1800ml or 2400ml of diluent.
1800 ml ali 2400 ml vehikla.
- (glass) ampoule of 1,000 doses of vaccine, 5-ampoule carrier.
- (steklena) ampula s 1,000 odmerki cepiva, nosilec s 5 ampulami.
Do not mix with any other veterinary medicinal product except those mentioned in the above paragraph and the diluent supplied for use with the product.
Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini, razen z navedenimi zgoraj in vehiklom, ki je priložen za uporabo s tem cepivom.
Shelf life of the diluent in polyvinylchloride bags: 36 months at a temperature below 30°C.
Rok uporabnosti vehikla v polivinilkloridnih vrečkah: 36 mesecev pri temperaturi do 30 °C.
Do not use in breeding birds and birds in lay.
Ne uporabite pri vzrejnih pticah in pticah v obdobju valjenja.
• Rinse the ampoule with these 2 ml and then transfer the rinsing liquid into the diluent.
• S tema dvema mililitroma izperite ampulo in nato ta izpirek prenesite v vehikel.
Subcutaneous route: one single injection of 0.2 ml per chicken at the age of one day.
Pri subkutani uporabi - enkratno injiciranje 0,2-ml pripravljenega cepiva v podkožje piščanca, starega en dan.
The active substance being a principle of biological origin intended to active immunity is not within the scope of Regulation (EC) No 470/2009.
C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL) Učinkovina biološkega izvora namenjena vzbujanju aktivne imunosti, ni vključena v Uredbo(ES) št.
- (glass) ampoule of 2,000 doses of vaccine, 4-ampoule carrier.
- (steklena) ampula z 2,000 odmerki cepiva, nosilec s 4 ampulami.
Shelf life of the diluent in polypropylene bottles: 12 months at a temperature below 30°C.
Rok uporabnosti vehikla v polipropilenskih stekleničkah: 12 mesecev pri temperaturi do 30 °C.
Discard any ampoules that have been accidentally thawed.
Vsako ampulo, ki je bila nenamerno odtaljena, zavrzite.
Live recombinant vaccine against Infectious Bursal Disease and Marek's Disease.
Živo rekombinantno cepivo proti bolezni Gumboro in Marekovi bolezni.
The vaccine strain is a recombinant Herpesvirus of turkeys (HVT) expressing the protective antigen (VP2) of the Infectious Bursal Disease Virus (IBDV) strain Faragher 52/70.
Sev virusa v cepivu je rekombinantni puranji herpesvirus (HVT), ki izraža zaščitne antigene (VP2)
Manufacturer responsible for batch release
Izdelovalec odgovoren za sprostitev serije
Live vHVT013-69 recombinant virus, at least ......................................................... 3.6 to 5.0 log10 PFU Excipient ...................................................................................................................................... qs 1 dose Diluent:
živi rekombinantni virus vHVT013-69, najmanj ............................................................... 3,6 log10 PFU Pomožna snov ..................................................................................................................... q.s 1 odmerek
Read the package leaflet supplied with the vaccine vial before use.
Pred uporabo preberite navodilo, priloženo viali s cepivom.
Marketing authorisation holder Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein GERMANY
Imetnik dovoljenja za promet z zdravilom Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein
• Wear protective gloves and spectacles during the ampoule thawing and opening operations.
• Pri odtajanju in odpiranju ampule nosite zaščitne rokavice in očala.
- (polypropylene) bottle of 200ml of diluent - (polyvinylchloride) bag of 200ml, 400ml, 600ml, 800ml, 1000ml, 1200ml, 1400ml, 1600ml,
(polipropilenska) steklenica z 200 ml. - (polivinilkloridna) vrečka z 200 ml 400 ml, 600 ml, 1000 ml, 1200 ml, 1400 ml, 1600 ml, 1800 ml ali 2400 ml vehikla.
Active ingredient:
Zdraviln učinkovina:
For in ovo route:
Za in ovo dajanje:
Wear protective gloves and spectacles during the ampoule thawing and opening operations.
Pri odtajanju in odpiranju ampule nosite zaščitne rokavice in očala.
Do not use if cloudy.
Ne uporabljajte, če je vsebina motna.
PACKAGE LEAFLET FOR: Vaxxitek HVT+IBD suspension and solvent for suspension for injection
NAVODILO ZA UPORABO ZA: Vaxxitek HVT+IBD suspenzija in vehikel za suspenzijo za injiciranje
Vaxxitek HVT+IBD Suspension and solvent for suspension for injection
Vaxxitek HVT+IBD suspenzija in vehikel za suspenzijo za injiciranje
Shelf life of the reconstituted vaccine: up to 2 hours at a temperature below 25°C.
Rok uporabnosti po rekonstituciji: do dve uri pri temperaturi do 25 oC.
Apply the usual aseptic precautions to all administration procedures.
Pri vseh postopkih vnosa cepiva ravnajte v skladu s pravili asepse.
Store the vaccine in liquid nitrogen.
Cepivo shranjujete v tekočem dušiku.
STERILE DILUENT
STERILNI VEHIKEL
PACKAGE LEAFLET FOR STERILE DILUENT
NAVODILO ZA UPORABO STERILNI VEHIKEL
Dimethyl sulfoxide Dilution medium
Suspenzija: dimetilsulfoksid razrečilo
Merial Laboratoire Porte des Alpes Rue de l'Aviation 69800 Saint Priest France
MERIAL, Laboratoire Porte des Alpes Rue de l'Aviation
Subcutaneous or in ovo route.
Subkutana in in ovo uporaba
In the absence of specific studies, no other veterinary medicinal product should be administered concurrently with the product.
Ker ni podatkov posebnih raziskav, odsvetujemo sočasno uporabo tega cepiva z drugimi zdravili za uporabo v veterinarski medicini.
The vaccine must be administered by subcutaneous route or by in ovo route.
Cepivo se injicira ali subkutano ali in ovo.
Live vHVT013-69 recombinant virus, at least ....................................................... 3.6 to 5.0 log10 PFU* Excipients .................................................................................................................................... qs 1 dose Diluent:
Vehikel: Vehikel ................................................................................................................................ q.s 1 odmerek
1 bag of 200 ml 1 bag of 400 ml 1 bag of 600 ml.
1 vrečka s po 200 ml 1 vrečka s po 400 ml 1 vrečka s po 600 ml 1 vrečka s po 800 ml 1 vrečka s po 1000 ml 1 vrečka s po 1200 ml 1 vrečka s po 1400 ml 1 vrečka s po 1600 ml 1 vrečka s po 1800 ml 1 vrečka s po 2400 ml
• Draw up 2 ml of the contents of the diluent into the syringe.
• V brizgo potegnite 2 ml vehikla.
ATCvet code QI01AD15
Oznaka ATCvet: QI01AD15 Živo rekombinantno cepivo proti bolezni Gumboro in Marekovi bolezni.
Suspension:
Odmerjanje
The full EPAR for Palonosetron Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Palonosetron Accord je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Palonosetron Accord has been shown to be comparable to Aloxi.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Palonosetron Accord primerljivo z zdravilom Aloxi.
What measures are being taken to ensure the safe and effective use of Palonosetron Accord?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Palonosetron Accord?
It is available as a solution for injection or infusion (drip) into a vein, which should be given by a healthcare professional about 30 minutes before the start of chemotherapy.
Na voljo je v obliki raztopine za injiciranje ali infundiranje (kapalne infuzije) v veno, ki jo mora dati zdravstveni delavec približno 30 minut pred začetkom kemoterapije.
Because Palonosetron Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Palonosetron Accord generično zdravilo, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
This is a summary of the European public assessment report (EPAR) for Palonosetron Accord.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Palonosetron Accord.
The Committee recommended that Palonosetron Accord be approved for use in the EU.
Priporočil je, da se zdravilo Palonosetron Accord odobri za uporabo v EU.
What are the benefits and risks of Palonosetron Accord?
Kakšne so koristi in tveganja, povezani z zdravilom Palonosetron Accord?
A risk management plan has been developed to ensure that Palonosetron Accord is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Palonosetron Accord je bil pripravljen načrt obvladovanja tveganj.
Other information about Palonosetron Accord
Druge informacije o zdravilu Palonosetron Accord
This means that Palonosetron Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Aloxi.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Aloxi.
Palonosetron Accord should only be given before chemotherapy.
Zdravilo Palonosetron Accord se sme dati samo pred kemoterapijo.
What is Palonosetron Accord and what is it used for?
Kaj je zdravilo Palonosetron Accord in za kaj se uporablja?
It may be given with a corticosteroid (another type of medicine that can be used to prevent nausea and vomiting) to increase the effect.
Za povečanje učinkovitosti se mu lahko doda kortikosteroid (druga vrsta zdravila, ki se lahko uporablja za preprečevanje slabosti in bruhanja).
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Palonosetron Accord, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Palonosetron Accord in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
By blocking these receptors, Palonosetron Accord prevents the nausea and vomiting that often happen after chemotherapy.
Zdravilo Palonosetron Accord z zaviranjem teh receptorjev prepreči slabost in bruhanje, ki se pogosto pojavita po kemoterapiji.
For more information about treatment with Palonosetron Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Palonosetron Accord preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
For practical information about using Palonosetron Accord, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Palonosetron Accord naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Palonosetron Accord is a medicine used to prevent nausea (feeling sick) and vomiting caused by chemotherapy (medicines to treat cancer).
Zdravilo Palonosetron Accord se uporablja za preprečevanje navzeje (slabosti) in bruhanja, ki ju povzroča kemoterapija (zdravila za zdravljenje raka).
The active substance in Palonosetron Accord, palonosetron, is a ‘5HT3 antagonist'.
Zdravilna učinkovina zdravila Palonosetron Accord, palonosetron, je „antagonist 5HT3“.
It is not intended to provide practical advice on how to use Palonosetron Accord.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
In children, the solution should be given by infusion into a vein over 15 minutes at a dose of 20 micrograms per kilogram body weight.
Pri otrocih se raztopina v odmerku 20 mikrogramov na kilogram telesne mase daje s 15-minutnim infundiranjem v veno.
Why is Palonosetron Accord approved?
Zakaj je bilo zdravilo Palonosetron Accord odobreno?
Palonosetron Accord contains the active substance palonosetron.
Zdravilo Palonosetron Accord vsebuje zdravilno učinkovino palonosetron.
No additional studies were needed as Palonosetron Accord is a generic medicine that is given by injection and contains the same active substance as the reference medicine, Aloxi.
Ker je zdravilo Palonosetron Accord generično zdravilo, ki se daje z injekcijo in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Aloxi, niso bile potrebne nobene dodatne študije.
How is Palonosetron Accord used?
Kako se zdravilo Palonosetron Accord uporablja?
How has Palonosetron Accord been studied?
Kako je bilo zdravilo Palonosetron Accord raziskano?
How does Palonosetron Accord work?
Kako zdravilo Palonosetron Accord deluje?
the change to the authorisation is Eli Lilly.
Družba, ki je vložila vlogo za spremembo dovoljenj za promet z zdravilom, je Eli Lilly.
It may request a retive opinion.
Predlagatelj je zaprosil za ponovni pregled mnenja.
There was also insufficient evidence th time, which is important when treating a long-term condition.
Prav tako ni bilo zadostnih dokazov, da je ta učinek mogoče vzdrževati dlje časa, kar je pomembno pri zdravljenju dolgotrajnih bolezni.
Neurotransmitters are chemica cells to communicate with one another.
Nevrotransmitorji so kemične snovi, ki omogočajo medsebojno komunikacijo živčnih celic.
The CHMP noted that the studies had not proven that duloxetine would provide a r the indication applied for.
Odbor CHMP je ugotovil, da študije niso dokazale, da duloksetin omogoča bistvene koristi pri indikaciji, za katero je bilo vloga vložena.
It works by preventi the neurotransmitters 5-hydroxytrypamine (also called serotonin) and no back up into nerve cells in the brain and spinal cord.
Deluje tako, da preprečuje ponovni privzem nevrotransmitorjev 5-hidroksitripamina (imenovanega tudi serotonin) in noradrenalina v živčne celice v možganih in hrbtenjači.
What consequences does this refusal have for patients in clin compassionate use programm
Kakšne posledice ima ta zavrnitev za bolnike, ki sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe?
What were the CHMP's main concerns that led to the refusal to the
Kateri so bili glavni zadržki CHMP, ki so privedli do zavrnitve spremembe dovoljenj za promet z zdravili?
Ariclaim is used to treat pain due to diabetic peripheral neuropathy (damage extremities that can occur in patients with diabetes).
Zdravilo Ariclaim se uporablja za zdravljenje bolečin zaradi diabetične periferne nevropatije (poškodbe živcev v okončinah, ki se pojavljajo pri bolnikih s sladkorno boleznijo).
MP) adopted a negative opinion, recommending the refusal of a change to the marketing authorisations for the duloxetinecontaining medicines Ariclaim, Cymbalta and Xeristar.
Dne 21. julija 2011 je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel negativno mnenje, s katerim priporoča zavrnitev spremembe dovoljenj za promet z zdravili Ariclaim, Cymbalta in Xeristar, ki vsebujejo duloksetin.
In addition to their approved uses, the three medicines were expected to be used to treat moderate to severe chronic (long-term) somatic pain in patients not regularly taking NSAID pain killers (nonsteroidal anti-inflammatory drugs).
Poleg odobrenih načinov uporabe so nameravali vsa tri zdravila uporabljati za zdravljenje zmerne do hude kronične (dolgotrajne) somatske bolečine pri bolnikih, ki ne jemljejo protibolečinskih zdravil NSAID (nesteroidnih antirevmatikov).
ts of five main studies in 839 patients with chronic somatic pain: two studies in patients with knee pain caused by osteoarthritis (swelling and pain in the joints) and three in ne or placebo (a nts taking them in combination with NSAIDs.
Družba je predstavila rezultate petih glavnih študij pri 839 bolnikih s kronično somatsko bolečino: dve študiji pri bolnikih z bolečino v kolenu, ki jo je povzročil osteoartritis (otekanje in bolečina v sklepih) in tri študije pri bolnikih s kronično bolečino v križu.
Since these neurotransmitters are i of pain, blocking their re-uptake into nerve cells may improve the symptoms of p
Ker ti nevrotransmitorji sodelujejo pri zmanjševanju občutka bolečine, se lahko z zaviranjem njihovega ponovnega privzema v živčne celice izboljšajo tudi simptomi bolečine.
The change concerned the addition of a new e chronic somatic pain in patients not taking NSAIDs regularly.
Sprememba se je nanašala na dodatek nove indikacije, zdravljenja zmerne do hude kronične somatske bolečine pri bolnikih, ki ne jemljejo redno nesteroidnih antirevmatikov.
Somatic pain is from the body surfaces (such as skin) or
Somatska bolečina izvira s telesnih površin (na primer s kože) ali iz mišično-skeletnih tkiv (kot so skeletne mišice, kosti in sklepi).
It does not include pain from h and intestines.
Ne vključuje pa bolečine, ki izvira iz notranjih organov, kot so želodec in prebavila.
Ariclaim, Cymbalta and Xeristar are medicines containin
Ariclaim, Cymbalta in Xeristar so zdravila, ki vsebujejo zdravilno učinkovino duloksetin.
By blocking their re-uptake, dul of these neurotransmitters in the spaces between these nerve cel communication between the cells.
Duloksetin z zaviranjem njihovega ponovnega privzema poveča količino teh nevrotrasmitorjev v prostorih med živčnimi celicami, s čimer se poveča stopnja komunikacije med celicami.
Patients in the studies were treated with duloxeti dummy treatment) with some patie effectiveness was the change in the severity of pain, as recorded by the patients after 12 or 13 weeks of treatment.
Glavno merilo učinkovitosti je bila sprememba resnosti bolečine, kot so jo vsakodnevno zabeležili bolniki na podlagi 11-točkovne lestvice po 12 ali 13 tednih zdravljenja.
The medicines are expected to work in the same way they do in diabetic periphera active substance duloxetine, is a serotonin-noradrenaline re-uptake inhibitor.
Zdravilna učinkovina duloksetin je zaviralec ponovnega privzema serotonina in noradrenalina.